港股通医疗ETF（520510）跟踪港股通医疗主题指数，覆盖阿里健康、京东健康、平安好医生等AI医疗 标的，有望受益于脑机接口、创新药出海及AI医疗技术革命。 港股市场年后表现持续强势，医疗、医药板块高弹性特点突出，港股通医疗ETF（520510）盘中大涨超 4%！年内涨幅突破20%，恒生医药ETF（159892）年内涨幅一度突破17%，在全市场ETF中涨幅靠前， 方舟健客盘中大涨超30%。 浙商证券认为，AI+医疗应用多点开花，政策支持与市场需求共振推动行业进入商业化落地快速阶段。 AI医疗应用方面，产业政策明确且进展迅速：2025年五部委印发相关实施意见、2026年初ChatGPT Health推出、蚂蚁阿福月活翻倍至3000万等持续催化市场热度。 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不 对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担 全部责任。邮箱：news_center@staff.hexun.com ...

板块方面，AI应用、商业航天、光伏、零售、贵金属等板块涨幅居前，油气、煤炭等方向跌幅居前。 周一，A股三大指数再度收涨，沪指涨1.09%收获17连阳，再度刷新逾10年高点。 单日成交额超3.6万亿元，又创历史新高，足见市场情绪之亢奋。 巨量成交背后，"AI+"概念今日再度爆发。 盘面上，AI医疗、AI营销、Sora概念、智谱AI、多模态AI、AIGC各类概念涨幅领先。受AI医疗概念的催化，医疗器械ETF(562600)今日上涨2.27%，今年 以来大幅上涨11.66%。 到底发生了什么？ 01 "AI+"集中爆发 具体来看，商业航天概念股反复活跃，鲁信创投12天10板，金风科技5连板，通宇通讯4天3板，杭萧钢构3连板，天奥电子、中国卫星涨停。 | 商业航天概念股表现 | | | | --- | --- | --- | | 还原 涨幅 : 现价 | 涨速 | 大单净额 | | 天润科技 | +30.00% 34.93 +0.00% | +7677.06万 | | 屋图测控 | +29.99% 130.16 +0.00% | +2.27亿 | | +29.92% 流金科技 | 9.51 +0.00% | +3.3 ...

每日经济新闻 创新药在药企国际化能力提升与产业政策支持下，景气度和市场风险偏好持续提升，中国创新药资产的 全球竞争力获广泛共识。 CXO则受益于降息周期开启+本土创新驱动，大周期拐点或现，美联储降息带来流动性宽松，国内创新 药二级市场好转有望带动一级市场投融资回暖，海外需求复苏将改善CXO需求和业绩。 从二级市场表现来看，恒生生物科技指数年内涨幅逼近14%，领涨港股关键指数，高弹性特征突出。截 至1月9日，恒生医药ETF（159892）年内获得超8亿资金申购，份额增长超13%，在港股医药、医疗赛 道位列第一。 恒生生物科技指数是恒生指数公司于2019年推出的反映港股市场生物科技板块整体表现的指数，相较于 高度聚焦于创新药的指数，恒生生物科技指数同时兼顾上游的CXO及AI医疗，能更准确的捕捉创新药 全产业链表现。 ...

中国AI核心资产：恒生科技指数ETF（513180） 高弹性特征突出：港股通科技ETF（159101） 聚焦创新药产业：恒生医药ETF（159892） 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 12月23日，人民币对美元中间价调升49个基点，报7.0523，创2024年9月30日以来最高。前一交易日中 间价报7.0572，在岸人民币16:30收盘价报7.0382，夜盘收报7.0368。 随着全球无风险利率的下行和人民币汇率的上涨，港股资产在全球的定价有望抬升；在南向资金加速入 场、外资回流的背景下，相对充裕的流动性也将支撑港股表现。 以高盛首席中国股票策略师刘劲津为首的分析师团队预计，2026年中国股票将延续涨势。中国股市周期 正从"预期驱动"转向"盈利驱动"，盈利兑现与估值温和扩张将成为推动回报的核心动力。 相关ETF： ...

12月11日，美联储如期宣布降息25个基点，并暗示未来将暂缓进一步降息，隔夜美股集体收涨。港股三 大指数今日集体高开，恒指涨0.66%，国指涨0.58%，恒生科技指数涨0.55%。科技股普遍上涨，白银价 格持续大涨创新高，黄金、铜等有色金属股继续强势，苹果概念股、航空股、保险股普涨，而电信运营 股走低。港股消费板块高开后略有震荡，现涨幅有所收窄，港股消费ETF（513230）盘中一度涨近 1%，现小幅微涨。其持仓股中，古茗、哔哩哔哩-W、思摩尔国际、新秀丽、创科实业等涨幅靠前，巨 子生物、统一企业中国、中国飞鹤、安踏体育等跌幅靠前。 消息面来看，北京时间周四凌晨，美联储联邦公开市场委员会（FOMC）发布了最新的利率决议，宣布 降息25个基点，将联邦基金利率目标区间降至3.50%~3.75%，符合市场"鹰派降息"预期。 美联储降息打 开估值空间，并通过真实资金流入显著改善"分子端"的流动性与盈利预期，叠加南向资金与政策红利形 成合力，港股有望迎来新一轮上行周期。 港股核心宽基：恒生ETF（159920） AI+平台经济：恒生科技指数ETF（513180） 交银国际认为，2025年消费小幅回暖，展望2026年，消 ...

Core Viewpoint - The launch of the Hang Seng Biotechnology Index futures contracts marks a significant enhancement in the investment landscape of the biotechnology sector in Hong Kong, indicating the sector's growing importance in thematic investments [1][2]. Group 1: Market Impact - The introduction of the Hang Seng Biotechnology Index futures is the first new index futures trading product in the Hong Kong stock market in the past five years, reflecting the increasing prominence of the pharmaceutical industry [1]. - The new futures contracts are expected to attract substantial new capital to the index constituent stocks, thereby injecting new momentum into the long-term development of the sector [1][2]. - The biotechnology sector is characterized by high growth potential and volatility, making the new futures an essential risk management tool for investors [1]. Group 2: Investment Opportunities - The collaboration between index futures products and ETFs is anticipated to optimize the capital ecosystem of the biotechnology industry, attracting institutional investors such as quantitative and hedge funds, which will enhance liquidity and pricing efficiency [2]. - Ordinary investors can conveniently participate in the growth of the biotechnology sector through the Hang Seng Medical ETF (159892), which focuses on innovative drugs and related industries [2]. - The Hang Seng Medical ETF is expected to continue its value re-evaluation trend under the "innovation + going global" theme, benefiting from the advantages of the Hong Kong Stock Exchange's 18A system [2]. Group 3: Market Performance - Similar index derivatives have demonstrated strong market vitality, as evidenced by the Hang Seng Technology Index futures, which have seen a 31% increase in average daily trading volume to 155,800 contracts in the first three quarters of 2025 compared to the entire year of 2024 [1]. - Over five years, the average daily trading volume of the Hang Seng Technology Index futures has surged by 8,800%, with its market share rising to 23%, highlighting the robust demand for risk management tools in high-volatility sectors [1].

Core Viewpoint - The innovative drug market has seen a significant surge, with Innovent Biologics experiencing over 150% growth year-to-date and a market capitalization exceeding HKD 160 billion [1] Group 1: Market Performance - The Hang Seng Biotechnology Index, which heavily invests in Innovent Biologics and BeiGene, has risen over 80% this year, ranking among the top in overall market indices [1] - The Hang Seng Medical ETF (159892) leads its category with a scale exceeding HKD 6 billion [1] Group 2: Upcoming Developments - The futures for the Hang Seng Biotechnology Index are set to be listed on the Hong Kong Stock Exchange on November 28, providing new risk hedging tools for investors [1] - Innovent Biologics will be included in the Hang Seng Index and the Hang Seng China Enterprises Index, with changes effective after market close on December 5 and effective on December 8 [1] Group 3: Fund Inflows - According to CICC's estimates, the ETF tracking the Hang Seng Index has a fund scale of approximately USD 29.2 billion, while those tracking the China Enterprises and Hang Seng Technology indices have scales of about USD 7.59 billion and USD 32.61 billion, respectively [1] - Innovent Biologics is expected to see an estimated inflow of over USD 364 million due to its inclusion in these indices [1]

Core Viewpoint - Recent dovish signals from the Federal Reserve officials indicate that there is still room for further interest rate cuts in the short term due to a weakening labor market, which has significantly boosted market confidence and led to a rebound in the Hong Kong stock market [1] Economic Indicators - The U.S. unemployment rate rose to 4.4% in September, the highest level since October 2021 [1] - The probability of a 25 basis point rate cut by the Federal Reserve in December is currently close to 70%, up from 30% a week ago [1] Market Implications - Despite short-term disruptions in the Fed's rate cut schedule, the backdrop of potential rate cuts may lead to unexpected foreign capital inflows, coupled with sustained increases in southbound capital [1] - The Hong Kong stock market is expected to experience further liquidity easing, particularly benefiting sectors that are more sensitive to liquidity, such as technology and pharmaceuticals [1] Related ETFs - Hong Kong innovative drug industry: Hang Seng Pharmaceutical ETF (159892) [1] - Hong Kong market AI sector: Hang Seng Technology Index ETF (513180) [1]

Group 1 - The core viewpoint of the article highlights the resilience of the Hong Kong biotechnology sector, particularly the Hang Seng Biotechnology Index, which is experiencing an upward trend despite broader market adjustments [1] - The Hong Kong Stock Exchange announced plans to launch Hang Seng Biotechnology Index futures on October 14, 2023, with trading set to begin on November 28, 2025, providing investors with precise risk management tools [1] - The introduction of index futures will make the Hang Seng Biotechnology Index the only index in the Hong Kong stock market with index futures in the pharmaceutical and healthcare sector [1] Group 2 - According to Shenwan Hongyuan, China has become the global leader in the number of clinical trials for innovative drugs over the past decade, transitioning from a "fast follower" to an "innovation leader" in research and development [1] - Domestic pharmaceutical companies are leveraging significant advantages in research and development efficiency, with extensive investments in new targets, new technology platforms, and challenging indications [1]

Core Viewpoint - The expectation for a Federal Reserve interest rate cut in December has diminished, leading to significant adjustments in key indices of A-shares and Hong Kong stocks, while the Hang Seng Biotechnology Index experienced a rapid rebound [1] Group 1: Market Performance - The Hang Seng Biotechnology Index, launched by the Hang Seng Index Company in 2019, reflects the overall performance of the biotechnology sector in the Hong Kong stock market [1] - The index not only focuses on innovative drugs but also incorporates upstream CXO companies, providing a more comprehensive view of the entire innovative drug industry chain [1] - Notable stocks leading the index's performance include Kingsoft Biotech, JD Health, Hansoh Pharmaceutical, and 3SBio [1] Group 2: Derivative Products - The Hong Kong Stock Exchange announced plans to launch futures for the Hang Seng Biotechnology Index on October 14, 2023, enhancing its expanding ecosystem of derivative products [1] - The new futures contract is set to begin trading on November 28, 2025, offering investors precise risk management tools [1] - The Hang Seng Biotechnology Index is the only index in the Hong Kong pharmaceutical and healthcare sector that has index futures available [1]